Table 2.

Effects of monoclonal antibodies-based angiogenic therapies on TAMs

Monoclonal Antibodies- Based Therapeutic Agent	Molecular Target	Tumor Type	TAM Effect	Ref.
Bevacizumab	VEGFA	Glioblastoma	Induces Tie-2+ monocyte infiltration and vast infiltration of M2-like macrophages	86
			Increases phosphorylation of STAT3 in macrophages, promoting a tumor supportive phenotype	89
Crossmab，A2V	Angiopoietin-2/ VEGFA bispecific		Transits TAM from M2-like phenotype to M1-like phenotype. Prolonging tumor-bearing mice survival time	84
MEDI3617	Angiopoietin-2		Promoting tumor vessel normalization and M1-like polarization of TAM when coadministered with cediranib	83
Cetuximab	Epidermal growth factor receptor	Colorectal carcinoma	Increases phagocytosis by macrophages to eliminate circulating cancer cells	72
			Activation of M2-like macrophages	85
		Heck and neck cancer	Ameliorates suppressive phenotypes of Fcγ receptor bearing myeloid cells in cancer patients	112
Trastuzumab	HER2	HER2+ breast cancers	Decreases CD68+ macrophage infiltration	75
SR1	c-Kit	Imatinib resistant GIST	Increases phagocytosis in macrophages	73

Abbreviations: EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2.